Efficacy and toxicity evaluation
toxicity, PD, tumor, SD
ADVERSE EVENT, TUMOR, PROGRESSIVE DISEASE, DISEASE, PRIMARY TUMOR
The clinical response of each participant was evaluated by endoscopy and CT. Evaluation of treatment response was performed in line with the RECIST version 1.1. Complete response (CR) signified complete tumor disappearance and absence of viable cells in biopsy tissue samples. Partial response (PR) signified a reduction in the sum of target disease of ≥30%. Progressive disease (PD) signified a ≥ 20% increase in the primary tumor. Stable disease (SD) was between PR and PD. In addition, toxicity was evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.